Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

16.02
-0.4000-2.44%
Volume:1.75M
Turnover:27.80M
Market Cap:1.90B
PE:-13.84
High:16.35
Open:16.24
Low:15.45
Close:16.42
Loading ...

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

CNW Group
·
17 Mar

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
17 Mar

Arcutis Biotherapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
12 Mar

Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies

TIPRANKS
·
12 Mar

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Simply Wall St.
·
09 Mar

Arcutis Biotherapeutics announces new data from two posters at 2025 AAD

TIPRANKS
·
07 Mar

Arcutis Biotherapeutics Inc - Zoryve Cream 0.15% Shows Favorable Safety and Tolerability in Ad Patients

THOMSON REUTERS
·
07 Mar

Arcutis to Highlight Data From Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83Rd American Academy of Dermatology Meeting

THOMSON REUTERS
·
07 Mar

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

GlobeNewswire
·
07 Mar

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average

Zacks
·
06 Mar

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
06 Mar

Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates

Stock Track
·
01 Mar

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

GlobeNewswire
·
28 Feb

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.
·
28 Feb

Arcutis Biotherapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
28 Feb

Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb